Congress approves $1.5 million for first-ever psoriasis patient registry at CDC

NewsGuard 100/100 Score

Millions of Americans suffering from psoriasis and psoriatic arthritis got a year-end boost from the federal government when it approved $1.5 million for the first-ever psoriasis patient registry at the Centers for Disease Control (CDC).

By aggregating data from the profiles of thousands of people with psoriatic disease, the patient registry will provide much-needed insight into how psoriasis and psoriatic arthritis impact those affected. Patient registries for other chronic diseases have been credited with improving treatment by as much as 50 percent through helping researchers and clinicians discover critical patterns in treatments and outcomes.

A disabling and disfiguring disease that appears on the skin, psoriasis is the most prevalent autoimmune condition in the country, affecting as many as 7.5 million Americans. Up to 30 percent of people with psoriasis will also develop psoriatic arthritis.

"As an individual afflicted with psoriasis and psoriatic arthritis, I am excited to have a registry that will help discover why and how I developed this disease and what treatments are best for me to manage it," said Rick Seiden, chairman of the National Psoriasis Foundation Board of Trustees. "It will help answer questions such as, why did I develop serious psoriatic arthritis, while others with psoriasis did not?"

The approval of the $1.5 million by Congress was realized after months of effort from the National Psoriasis Foundation and its 58,000 advocates. In 2009, Psoriasis Foundation advocates sent more than 3,000 messages to their elected officials urging them to increase the investment in psoriasis research by the federal government. The cause was elevated on Capitol Hill further by singer -- and psoriasis patient -- LeAnn Rimes' trips to D.C. last year to advocate for the registry.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Shifting towards personalized treatment approaches for chronic inflammatory diseases